Table 1.

Data from the 24 included randomized controlled trials included in this systematic review and network meta-analysis.

Author	Year	Country	Trial Number	Total (N)	Breast (N)	Intervention (vs. WGL)
Postma	2012	Netherlands	NCT00539474	314	316	ROLL
Duarte	2016	Columbia	C41030610-019	129	129	ROLL
Medina-Franco	2008	Mexico	–	100	100	ROLL
Rampaul	2004	UK	–	93	93	ROLL
Martinez	2009	Spain	–	134	134	ROLL
Ocal	2011	Turkey	–	108	108	ROLL
Moreno	2008	Brazil	–	120	120	ROLL
Kanat	2016	Turkey	–	36	36	ROLL
Alikhassi*	2016	Iran	–	60	60	ROLL
Tang	2011	China	–	157	157	ROLL + Dye
Langhans	2017	Denmark	R72-A4701–13-S9	409	413	RSL
Taylor	2021	Australia	ACTRN12613000655741	659	664	RSL
Bloomquist	2015	USA	–	125	125	RSL
Lovrics	2011	Canada	NCT00225927	305	305	RSL
Parvez	2014	Canada	–	73	73	RSL
Gray	2001	USA	–	97	97	RSL
Rahusen	2002	Netherlands	–	49	49	USGL
Hoffman	2019	Germany	NCT02222675	47	47	USGL
Hu	2020	China	–	520	520	USGL
Tafra	2016	USA	–	320	320	CAL
Struik	2021	Netherlands	NL6553	67	67	ML
Tong	2019	China	–	62	62	IL
Israel	2002	USA	–	114	114	AGL
Barth Jr.	2019	USA	NCT01929395	137	137	SMRI

N; Number, WGL; wire-guided localization, ROLL; radio-guided occult lesion localization, RSL; radioactive seed localization, USGL; ultrasound-guided localization, CAL; cryo-assisted localization, ML; magnetic-marker localization, IL; indocyanine green fluorescence-guided lumpectomy, AGL; anchor-guided localization.

SMRI; intraoperative supine magnetic resonance imaging, UK; United Kingdom, USA United States of America.

*Incalculable at meta-analyses results reporting no positive results for the primary outcome of interest.